Abstracts tagged "Inflammation"

Abstract Number: 0297 • ACR Convergence 2022
Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Adriana Kakehasi², Neil Basu³, David A. Walsh⁴, Andra Balanescu⁵, Clifton Bingham⁶, Andrew Garrison⁷, Ivan Lagunes⁸, sander strengholt⁹, Ralph Lippe¹⁰ and Maxime Dougados¹¹, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴University of Nottingham, Nottingham, United Kingdom, ⁵University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ⁶Johns Hopkins University, Baltimore, MD, ⁷AbbVie, Inc., North Chicago, IL, ⁸AbbVie, Inc., Mettawa, IL, ⁹AbbVie, Inc., Abcoude, Netherlands, ¹⁰AbbVie, Inc, Wiesbaden, Germany, ¹¹Université de Paris, Paris, France
Background/Purpose: Residual pain remains a challenge that prevents patients (pts) with RA from achieving a better quality of life. Current RA treatments have demonstrated efficacy…
Abstract Number: 0590 • ACR Convergence 2022
Molecular Profiling of Normal Human Synovium Reveals Striking Impact of Adipocytes and Homeostatic Cortisol Signaling
Heather Faust¹, Tan-Yun Cheng¹, Ilya Korsunsky¹, Gerald FM Watts¹, David Moody¹ and Michael Brenner², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The synovium encapsulates joints and contains fibroblasts which proliferate, become invasive, and drive disease progression in rheumatoid arthritis (RA) and osteoarthritis (OA). There is…
Abstract Number: 0815 • ACR Convergence 2022
Hyper-IgG4 in Patients with Systemic Autoinflammatory Disease
Brianne Navetta-Modrov and QingPing Yao, Stony Brook University, Stony Brook, NY
Background/Purpose: Hyper-immunoglobulin G4 (IgG4) has been reported in various conditions including autoimmune disease, gastrointestinal disorders, lymphoproliferative/granulomatous diseases and solid tumors. IgG4-related disease is an immune-mediated…
Abstract Number: 1321 • ACR Convergence 2022
Systemic Inflammatory-based Scores and Bone Turnover Ratio as Novel Diagnostic Tools for Chronic Nonbacterial Osteomyelitis (CNO) of the Sternocostoclavicular Region in Adults
Anne Leerling, Juliette Faber, Natasha Appelman-Dijkstra, Olaf Dekkers and Elizabeth Winter, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Chronic non-bacterial osteomyelitis (CNO) in adults exhibits as sterile osteitis and consequent disrupted bone metabolism favoring bone formation of the sternocostoclavicular region (SCCH). Diagnosis…
Abstract Number: 1686 • ACR Convergence 2022
Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts
Austin Ragland¹, Michael Duryee¹, nozima Aripova¹, Spencer Jones¹, Ted Mikuls² and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Post-translational modifications with malondialdehyde-acetaldehyde (MAA) alter protein structure and function, inducing pro-inflammatory and pro-fibrotic responses characteristic of rheumatoid arthritis (RA). Matrix-gla protein (MGP) chelates…
Abstract Number: 1929 • ACR Convergence 2022
Outcomes and Safety of Anakinra for the Treatment of Multisystem Inflammatory Syndrome in Children
Dizon Brian¹, Christopher Redmond², Emily Gotschlich³, Sangeeta Sule⁴, Tova Ronis⁴, Kathleen Vazzana⁵, Matthew Sherman⁶, Rachael Connor⁷, Abigail Bosk⁴, Niti Dham⁴, Ashraf Harahsheh⁴, Elizabeth Wells⁴, Roberta DeBiasi⁴ and Hemalatha Srinivasalu⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Health, Rockville, MD, ³FDA, Washington, DC, ⁴Children's National Hospital, Washington, DC, ⁵Arnold Palmer Hospital for Children, Orlando, FL, ⁶Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH); Children’s National Hospital, Washington, DC, ⁷Children's National Medical Center, Washington, DC
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a clinical entity distinct from primary COVID-19 infection that resembles Kawasaki disease (KD) and toxic shock syndrome.…
Abstract Number: 0045 • ACR Convergence 2021
Endothelial Cells from Patients with DMARD Naïve, Active Inflammatory Arthritis Demonstrate Pro-inflammatory Sensitisation That Is Reversed by Therapy Initiation
Robert Maughan¹, Marie Lang¹, Anton Olsson¹, Andrew Porter¹, Antonia Greeves², Taryn Youngstein³, Charis Pericleous¹ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²Hammersmith Hospital, London, United Kingdom, ³Hammersmith Hospital & Imperial College London, London, United Kingdom
Background/Purpose: Inflammatory arthritides (IA) including rheumatoid arthritis are associated with increased cardiovascular disease (CVD) mortality. Although inflammation-driven endothelial dysfunction is considered a major factor, the…
Abstract Number: 0468 • ACR Convergence 2021
During Development of Rheumatoid Arthritis, Intermetatarsal Bursitis May Occur Before Clinical Joint Swelling: A Large MRI Study in Patients with Clinically Suspect Arthralgia
Bastiaan van Dijk¹, Fenne Wouters¹, Elise van Mulligen², Monique Reijnierse¹ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Inflammation of the synovial lining is a hallmark of rheumatoid arthritis (RA). A synovial lining is not only present at synovial joints and tendon…
Abstract Number: 1000 • ACR Convergence 2021
Molecular Mechanism of Inhibition of CD38 in Attenuation of Monosodium Urate Crystal-induced Inflammatory Responses in Macrophages
Huaping Qin¹, Patricia Oliveira¹, Tiffany Yan¹, Robert Terkeltaub² and Ru Liu Bryan³, ¹University of California San Diego, La Jolla, CA, ²VA/UCSD, San Diego, CA, ³University of California San Diego and VASDHS, San Diego, CA
Background/Purpose: CD38 can function as a degrading enzyme of nicotinamide adenine dinucleotide (NAD), a critical metabolic intermediate serving as enzyme cofactor in redox reactions and…
Abstract Number: 1349 • ACR Convergence 2021
Joint-specific Responses to Tofacitinib and Adalimumab in Patients with Psoriatic Arthritis: Post Hoc Analysis of a Phase 3 Study
Adrian Ciurea¹, Tim Killeen², Raphael Micheroli¹, Norina N Gassman², Hyejin Jo³, Kenneth Kwok⁴, Elizabeth Kudlacz⁴, Oliver Distler¹, Caroline Ospelt⁵ and Mojca Frank-Bertoncelj¹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ²Pfizer AG, Zurich, Switzerland, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Peripheral joint involvement in PsA varies. In RA, varied joint involvement may reflect site-specific differences in stromal cell transcriptome, including Janus kinase-signal transducer and…
Abstract Number: 1809 • ACR Convergence 2021
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
Philip Mease¹, Ana-Maria Orbai², Oliver FitzGerald³, Mohamed Bedaiwi⁴, Dona L Fleishaker⁵, Rajiv Mundayat⁶, Pamela Young⁷ and Philip S Helliwell⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Division of Rheumatology, College of Medicine, King Saud University Medical City, Riyadh, Saudi Arabia, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Enthesitis (inflammation where the tendon, ligament, or joint capsule insert into the bone) has been associated with higher disease activity and reduced quality of…
Abstract Number: 0049 • ACR Convergence 2021
CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis
Rajula Gaur, Kofi Mensah, Jason Stricker, Anastasia Parton, Dorota Cedzik and Francisco Ramírez-Valle, Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Mitogen-activated protein kinase-activated protein kinase-2 (MK2), a direct downstream target of p38, has been identified as a promising candidate for treatment of inflammatory diseases.…
Abstract Number: 0508 • ACR Convergence 2021
The Impact of Macrophages Stimulated with Malondialdehyde-Acetaldehyde And/or Citrulline Modified Proteins on Fibroblasts Activation
Nozima Aripova, Michael Duryee, Evan Ryan, Peter Maloley, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In rheumatoid arthritis (RA), chronic synovial inflammation is accompanied by fibrotic responses that together lead to pannus formation and progressive joint damage. Exposure to…
Abstract Number: 1001 • ACR Convergence 2021
Exosomes Mediate a Cooperative Mechanism of Macrophage/Fibroblast Activation in Systemic Sclerosis
Rajan Bhandari¹, Heetaek Yang², Noelle Kosarek³, Michael Whitfield⁴ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Geisel School of Medicine, Hanover, NH, ³Dartmouth Geisel School of Medicine, Hartford, VT, ⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Prior work demonstrates that macrophages (MØs) from patients with Systemic Sclerosis (SSc) produce fibrotic and pro-inflammatory mediators and that cocultured MØs and SSc fibroblasts…
Abstract Number: 1426 • ACR Convergence 2021
Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features
Marcela Ferrada¹, Sinisa Savic², Hugh Alessi³, Daniela Ospina⁴, Lorena Wilson⁵, Wendy Goodspeed⁶, Tannaz Kermani⁷, Kenneth Warrington⁸, Matthew Koster⁸, Bhavisha Patel⁹, Patrycja Hoffmann¹⁰, James Poulter¹¹, Rachel Tattersall¹², Amanda Ombrello¹, Christopher Duncan¹³, Elspeth Payne¹⁴, Karoline Krause¹⁵, Hanna Bonnekoh¹⁶, Daniel Kastner¹⁷, Peter Grayson¹⁸ and David Beck¹, ¹National Institutes of Health, Bethesda, MD, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³National Institutes of Health, Bethesda, Maryland, ⁴NIH/NHGRI, Bethesda, MD, ⁵National Institutes of Health, Silver Spring, MD, ⁶National Institutes of Health (NIH), Bethesda, MD, ⁷University of California Los Angeles, Los Angeles, CA, ⁸Mayo Clinic, Rochester, MN, ⁹National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ¹⁰National Institutes of Health, Vienna, VA, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Sheffield Teaching Hospitals NHS Foundation, Sheffield, United Kingdom, ¹³Translational and Clinical Research institute, Immunity and Inflammation Theme, Newcastle, United Kingdom, ¹⁴University College London, Cancer Institute, London, United Kingdom, ¹⁵Department of Dermatology and Allergy, Charité, Berlin, Germany, ¹⁶Department of Dermatology and Allergy, Charité, Berlin, United Kingdom, ¹⁷National Human Genome Research Institute, Bethesda, MD, ¹⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly defined disease cause by myeloid-restricted somatic mutations in blood. Missense mutations at codon…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].